|Antisense Therapeutics Ltd.|
6 - 8 Wallace Avenue
Australia - Map
Phone: 61 3 9827 8999
Fax: 61 3 9827 1166
Antisense Therapeutics Ltd. engages in the research, development, and commercialization of novel antisense pharmaceuticals in Australia. The companys product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of insulin like growth factor 1 receptor to treat prostate cancer. Its product pipeline also includes ATL1103, a second generation antisense drug to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action. The company has a partnership with Isis Pharmaceuticals, Inc. for the discovery and development of antisense drugs. Antisense Therapeutics Ltd. is based in Toorak, Australia.
|Mr. Mark Diamond BSc, MBA, MAICD,
Chief Exec. Officer, Managing Director and Director
|Mr. Phillip Allen Hains BBus(Acc), MBA, CA,
Chief Financial Officer and Company Sec.
|Dr. George Tachas ,
Director of Drug Discovery & Patents
| Susan Turner ,
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in AUD.|